Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Belantamab mafodotin in relapsed systemic AL amyloidosis

Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, briefly discusses the results of a study investigating the efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis. Overall, the study reported high overall response rates (ORR) in this patient population. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.